Detalhe da pesquisa
1.
Efficacy of tixagevimab-cilgavimab in preventing SARS-CoV-2 for patients with B-cell malignancies.
Blood
; 141(2): 200-203, 2023 01 12.
Artigo
Inglês
| MEDLINE | ID: mdl-36332185
2.
Role of tixagevimab-cilgavimab in preventing SARS-CoV-2 in hematopoietic stem cell transplant and chimeric antigen receptor T-cell therapy recipients.
J Med Virol
; 95(8): e29027, 2023 08.
Artigo
Inglês
| MEDLINE | ID: mdl-37548241
3.
Gastric adenocarcinoma following CD19-directed chimeric antigen receptor T cell therapy.
Ann Hematol
; 102(2): 461-462, 2023 02.
Artigo
Inglês
| MEDLINE | ID: mdl-36385650
4.
Polatuzumab Vedotin for the Front-Line Treatment of Diffuse Large B-Cell Lymphoma: A New Standard of Care?
J Adv Pract Oncol
; 14(1): 67-72, 2023 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-36741209
5.
Clinical utility of chromosomal microarray in establishing clonality and high risk features in patients with Richter transformation.
Cancer Genet
; 260-261: 18-22, 2022 01.
Artigo
Inglês
| MEDLINE | ID: mdl-34808593
6.
Dual target dilemma: navigating epcoritamab vs. glofitamab in relapsed refractory diffuse large B-cell lymphoma.
Expert Rev Hematol
; 16(12): 915-918, 2023.
Artigo
Inglês
| MEDLINE | ID: mdl-37982732
7.
Incidence of Pneumocystis jirovecii pneumonia (PJP) in patients receiving BTK inhibitors who did not receive PJP prophylaxis.
Leuk Lymphoma
; 63(8): 2016-2018, 2022 08.
Artigo
Inglês
| MEDLINE | ID: mdl-35341452